ADTX Aditxt, Inc.

Nasdaq aditxt.com


$ 4.84 $ -0.61 (-11.2 %)    

Friday, 14-Nov-2025 15:48:49 EST
QQQ $ 608.45 $ 0.46 (0.08 %)
DIA $ 471.65 $ -2.94 (-0.62 %)
SPY $ 671.62 $ -0.11 (-0.02 %)
TLT $ 88.93 $ -0.51 (-0.57 %)
GLD $ 375.82 $ -6.91 (-1.8 %)
$ 4.8396
$ 5.13
$ 4.84 x 49
$ 4.92 x 10
$ 4.55 - $ 5.24
$ 4.51 - $ 11,941.28
69,717
na
90,012
$ 2.38
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-15-2025 03-31-2025 10-Q
3 03-31-2025 12-31-2024 10-K
4 11-18-2024 09-30-2024 10-Q
5 08-19-2024 06-30-2024 10-Q
6 05-20-2024 03-31-2024 10-Q
7 04-16-2024 12-31-2023 10-K
8 11-14-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-15-2023 03-31-2023 10-Q
11 04-17-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-15-2022 06-30-2022 10-Q
14 05-16-2022 03-31-2022 10-Q
15 03-31-2022 12-31-2021 10-K
16 11-15-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-12-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-13-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aditxts-pearsanta-begins-enrollment-in-clinical-study-evaluating-mitomic-endometriosis-test-blood-based-diagnostic-designed-to-aid-in-early-detection-of-endometriosis

Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a non-in...

Core News & Articles

-- Special Meeting to be held on September 26, 2025 --SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders tod...

 aditxt-plans-fda-submission-for-first-in-human-trials-in-type-1-diabetes-and-stiff-person-syndrome-in-early-2026

Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for e...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION